Table 2 Percentage of leukocyte populations and cell ratios in nAMD patients and controls.
From: Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration
Variables | Controls (mean ± SD) n= 26 | nAMD (mean ± SD) n= 103 | Univariate analysis | Multivariate analysis (age and gender) | Multivariate analysis (age, gender, cardiovascular disease and aspirin intake) | ||||
|---|---|---|---|---|---|---|---|---|---|
P value nAMD vs Controls 1 | P value nAMD vs Controls 2 | Odds ratio | 95% confidence interval for odds ratio | P value nAMD vs Controls 3 | Odds ratio | 95% confidence interval for odds ratio | |||
Cell subsets (FSC/SSC plot) | |||||||||
Lymphocytes (%) | 30.45 ± 7.82 | 26.51 ± 6.97 | 0.013 | 0.033 | 0.94 | 0.88–0.99 | |||
Monocytes (%) | 7.28 ± 1.88 | 7.85 ± 2.58 | 0.292 | ||||||
Neutrophils (%) | 59.80 ± 8.73 | 63.71 ± 7.60 | 0.025 | 0.052 | 1.06 | 1.00–1.12 | |||
Neutrophil/Lymphocyte ratio | 2.16 ± 0.84 | 2.66 ± 1.08 | 0.016 | 0.037 | 17.56 | 1.19–258.21 | |||
Cell subsets (CD antigens) | |||||||||
CD14+ (%) | 7.35 ± 1.95 | 7.61 ± 2.24 | 0.628 | ||||||
CD4+ (%) | 12.21 ± 3.92 | 11.46 ± 4.25 | 0.301 | ||||||
CD8+ (%) | 5.86 ± 2.96 | 5.06 ± 3.49 | 0.137 | ||||||
CD19+ (%) | 3.41 ± 2.16 | 2.78 ± 1.48 | 0.126 | ||||||
CD56+ (%) | 3.27 ± 1.66 | 3.46 ± 1.94 | 0.834 | ||||||
CD11b+ (%) | 67.40 ± 9.00 | 72.77 ± 7.68 | 0.006 | 0.015 | 1.08 | 1.01–1.14 | |||
CD16hiHLA-DR− Neutrophils (%) | 57.80 ± 9.05 | 63.19 ± 7.87 | 0.003 | 0.009 | 1.07 | 1.02–1.13 | |||
CD16hiHLA-DR−/(CD4 + CD8) ratio | 3.51 ± 1.49 | 4.42 ± 1.88 | 0.031 | 0.072 | 10.24 | 0.81–129.24 | |||
CD16hiHLA-DR−/CD4 ratio | 5.34 ± 2.34 | 6.34 ± 2.74 | 0.100 | ||||||
CD16hiHLA-DR−/CD8 ratio | 13.80 ± 11.28 | 19.82 ± 16.22 | 0.051 | 0.072 | 3.97 | 0.88–17.88 | 0.041 | 5.66 | 1.07–29.79 |
CD16hiHLA-DR−/CD19 ratio | 25.69 ± 21.26 | 32.14 ± 26.91 | 0.085 | ||||||
CD16hiHLA-DR−/CD56 ratio | 22.41 ± 11.25 | 25.75 ± 19.89 | 0.714 | ||||||
